Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security - 2Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- 3Best Quest for new employment Site for You to Track down Amazing open doors
- 4The most effective method to Involve Handshakes for Compromise and Compromise
- 5The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- Manual for Financial plan Agreeable PC
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Skeleton of famed musketeer possibly found in Dutch church
- The most effective method to Pick the Best Material Organization: Insider Tips
- Figure out How to Score Huge with Open Record Rewards
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- In these U.S. groups, deaths now exceed births. What’s happening?
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Top 10 Arising Advances That Will Shape What's in store
